当前位置: X-MOL 学术OMICS › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Molecular Targets from Traditional Medicines for Neuroprotection in Human Neurodegenerative Diseases.
OMICS: A Journal of Integrative Biology ( IF 2.2 ) Pub Date : 2020-07-06 , DOI: 10.1089/omi.2020.0033
Sayali Chandrashekhar Deolankar 1 , Prashant Kumar Modi 1 , Yashwanth Subbannayya 1 , Ravishankar Pervaje 2 , Thottethodi Subrahmanya Keshava Prasad 1
Affiliation  

Neurodegeneration is one of the greatest threats to global public health. Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease are among the major causes of chronic neurological conditions in the elderly populations. Hence, neuroprotection is at the epicenter of the current 21st-century research agenda in biomedicine. Yet, novel molecular targets are limited and solely needed for neuroprotection. Marked person-to-person variations in outcomes require a deeper understanding of drug targets in neurology and clinical neurosciences. In this context, traditional medicines offer untapped potentials for discovery and translation of novel molecular targets to human neurodegenerative disease research and clinical neurology. This expert review offers a synthesis of the prospects and challenges of harnessing new molecular targets from traditional medicines, with a view to applications for neuroprotection in human neurodegenerative diseases.

中文翻译:

传统药物在人类神经退行性疾病中的神经保护作用的分子靶标。

神经变性是对全球公共健康的最大威胁之一。诸如阿尔茨海默氏病,帕金森氏病,肌萎缩性侧索硬化症和亨廷顿氏病等神经退行性疾病是老年人中慢性神经系统疾病的主要原因。因此,神经保护作用是当前21世纪生物医学研究议程的中心。然而,新的分子靶标是有限的,并且仅用于神经保护。人与人之间明显的结果差异需要对神经病学和临床神经科学中的药物靶点有更深入的了解。在这种情况下,传统药物为人类神经退行性疾病研究和临床神经病学发现和翻译新型分子靶标提供了未开发的潜力。
更新日期:2020-07-07
down
wechat
bug